TABLE 2.
Admission clinical data for 59 adults with TBM included in the study before the start of ATC
| Variable | No. (%) or median (range) |
|---|---|
| Male sex | 30 (50.8) |
| Age (yr) | 33 (15-69) |
| HIV infection | 5 (8.5) |
| Medical Research Council disease severity gradec | |
| I | 17 (28.8) |
| II | 29 (49.2) |
| III | 13 (22.0) |
| Duration of symptoms before treatment (days) | 15 (5-35) |
| Vol of CSF (ml) | 4.0 (1-12) |
| CSF opening pressure (cm H2O) | 23 (6-40) |
| CSF total white cells (103/ml) | 461 (1-1,750) |
| % Neutrophils | 27 (0-90) |
| % Lymphocytes | 73 (10-100) |
| CSF protein (mg/dl) | 169 (66-4700) |
| CSF lactate (mmol/liter) | 5.8 (1.1-16.4) |
| CSF chloride (mmol/liter) | 104 (84-129) |
| CSFblood glucose ratio | 0.25 (0.05-0.67) |
| 9-mo survival | 45 (76.3) |
a
See reference 14.